The short answer
Cholangiocarcinoma starts in the bile ducts. Where it starts shapes symptoms and surgery, and molecular testing for FGFR2 fusions or IDH1 mutations can open targeted treatment options.
Bile duct cancer is grouped as intrahepatic (inside the liver) or extrahepatic (perihilar and distal), and that location shapes symptoms, surgery and treatment.
Surgery is the only treatment that can cure cholangiocarcinoma, but only a minority of tumors can be removed at the time of diagnosis.
Next-generation sequencing of the tumor matters here: FGFR2 fusions (pemigatinib, futibatinib) and IDH1 mutations (ivosidenib) have FDA-approved targeted drugs.
For advanced disease, adding durvalumab or pembrolizumab to gemcitabine and cisplatin chemotherapy improved survival in clinical trials.
Choose how you want to understand this
The full explanation.
What cholangiocarcinoma is
Cholangiocarcinoma is cancer that starts in the bile ducts, the thin tubes that carry bile from your liver and gallbladder into your small intestine. It is uncommon, and most people have never heard the word before the day they are diagnosed.
Doctors group it by where it starts, because location changes almost everything that follows.
- Intrahepatic cholangiocarcinoma begins in the smaller ducts inside the liver.
- Perihilar cholangiocarcinoma begins where the main ducts leave the liver.
- Distal cholangiocarcinoma begins lower down, near the pancreas.
Perihilar and distal tumors are together called extrahepatic. Because they sit in the drainage path, they more often block bile and cause jaundice: yellow skin and eyes, dark urine, pale stools, and itching. Intrahepatic tumors are more often found because of vague abdominal pain, weight loss, or a scan done for another reason.
How it is diagnosed
Work-up usually includes CT and MRI with MRCP, a scan that maps the bile ducts. Blood tests check liver function and often the marker CA 19-9. An endoscopic procedure such as ERCP or endoscopic ultrasound may be used to take samples and, if a duct is blocked, to place a stent that lets bile drain again.
Getting enough tissue matters twice over: once to confirm the diagnosis, and again for molecular testing.
Can it be removed?
The central early question is whether the tumor can be removed with surgery. Surgery is the only treatment that can cure cholangiocarcinoma. It is a large operation, usually a partial hepatectomy for intrahepatic and perihilar disease, or a Whipple procedure for distal disease. Only a minority of people are candidates when they are diagnosed.
Being told a tumor is unresectable is not the end of treatment. It changes which treatments are on the table, and it is a reason to ask for a second opinion at a center that does high volumes of liver and bile duct surgery.
Why molecular testing matters here
Bile duct cancer has become one of the clearer examples of targeted treatment in gastrointestinal cancer. Ask whether your tumor has had next-generation sequencing. Changes that have led to approved drugs include:
- FGFR2 fusions or rearrangements, found mostly in intrahepatic tumors, treated with FGFR inhibitors such as pemigatinib or futibatinib.
- IDH1 mutations, also mostly intrahepatic, treated with ivosidenib.
- Other findings, such as HER2 amplification, BRAF V600E, or high microsatellite instability, which may open trial or off-label options.
Results can take two to four weeks. It is reasonable to ask when the test was sent and when it is due back, because the answer can change your next line of treatment.
Treatment for advanced disease
For cancer that cannot be removed, the long-standing chemotherapy backbone is gemcitabine with cisplatin. Trials then showed that adding an immunotherapy drug, either durvalumab or pembrolizumab, improved survival, and both combinations are now approved for advanced biliary tract cancer. The gain is real but modest, and not everyone is a candidate, so ask what it means in your specific case.
Other chemotherapy combinations, including FOLFOX and gemcitabine with oxaliplatin, are used after first-line treatment. When disease is confined to the liver, local approaches such as radiation, radioembolization or ablation are sometimes considered.
Living alongside treatment
Blocked bile ducts and the infection that follows, called cholangitis, are the complications most likely to interrupt treatment. Fever, chills, worsening jaundice, or new severe abdominal pain should be reported the same day rather than at your next visit.
Palliative care alongside cancer treatment is not giving up. It is the team that manages itching, pain, appetite and fatigue while your oncologist manages the cancer. Nutrition support matters too, because bile flow affects how well you absorb fat.
Clinical trials carry unusual weight in this disease because the field is moving quickly. Asking about them early, rather than after other options are exhausted, gives you the widest set of choices.
Sources
Words to know
Tap any term to see what it means.
Common questions
What is the difference between intrahepatic and extrahepatic bile duct cancer?
Intrahepatic cholangiocarcinoma starts in the small bile ducts inside the liver and is often found as a mass on a scan. Extrahepatic disease (perihilar and distal) starts in the larger ducts outside the liver and more often blocks bile flow, causing jaundice. The two groups differ in surgery, in which mutations are common, and in how they are followed.
Should my tumor have genomic testing?
Comprehensive molecular testing is standard practice in cholangiocarcinoma, especially for intrahepatic tumors. It looks for FGFR2 fusions, IDH1 mutations, HER2 amplification, BRAF V600E, microsatellite instability and other findings that can point to approved drugs or trials. Ask when the test was sent and when results are expected.
Why do I need a stent?
A stent is a small tube placed during an endoscopic or radiology procedure to hold a blocked bile duct open. Relieving the blockage lowers bilirubin, reduces itching and jaundice, and often has to happen before chemotherapy can be given safely. Stents can clog over time and sometimes need replacing.
Does immunotherapy help in bile duct cancer?
On its own, immunotherapy has limited activity in most bile duct cancers. Added to gemcitabine and cisplatin chemotherapy, durvalumab and pembrolizumab each improved survival in randomised trials and are approved for advanced biliary tract cancer. The benefit is real but modest, so it is worth asking what it means for your situation.
What is CA 19-9?
CA 19-9 is a blood marker that is often, but not always, raised in bile duct cancer. It can also rise simply because a duct is blocked. It is used alongside scans to follow how treatment is working, not as a standalone measure of how you are doing.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Speak With Trained Specialists & Human Navigators
Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.
Talk to a trained cancer information specialist
Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.
Contact your oncology team
Locate after-hours contact numbers, portal messages, or urgent triage phone lines.
Find a patient navigator
Get one-on-one help with appointments, logistics, translation, and care coordination.
Find a genetic counselor
Discuss inherited mutation risk, family history, and genetic testing options.
Find an oncology social worker
Access emotional counseling, family support groups, and mental health resources.
Find a financial navigator
Locate copay assistance foundations, grant programs, and lodging/travel support.
Find a clinical-trial specialist
Search matching studies and speak with NCI trial information specialists.
Get urgent help
Immediate emergency guidance for fever (>100.4°F during chemo), severe pain, or shortness of breath.
Help Us Improve This Guide
Did this explanation answer your question and help you determine your next step?
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Plain-language explanation of the federal sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.
Written by: Cancer Explained Editorial TeamSources last checked: 2026-07-30Last updated: 2026-07-30Next planned review: 2028-07-29
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status — Source verified. This page was created with AI assistance and checked against the sources listed on it. Source checking is not a medical review.
General education. Low-risk educational or organizational content. Medical facts are cited to authoritative sources.
Human medical review: not completed. Cancer Explained is not clinician-reviewed, and that is a deliberate design choice rather than a gap we are waiting to close. We restate published federal guidance and cite it; the authority belongs to the source, not to us. That is why every page names where its claims come from — so you can verify us instead of trusting us. Use it to understand your situation and to ask better questions of the people treating you.
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status: Source verified — This page was created with AI assistance and checked against the sources listed on it. Source checking is not a medical review.
Human medical review: not completed. Cancer Explained is not clinician-reviewed, and that is a deliberate design choice rather than a gap we are waiting to close. We restate published federal guidance and cite it; the authority belongs to the source, not to us. That is why every page names where its claims come from — so you can verify us instead of trusting us. Use it to understand your situation and to ask better questions of the people treating you.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.
Related articles
Still have questions?
Educational answers, plain language
Free to print and share